Adaptive Biotech Q2 revenue $43.7M (+13% YoY); MRD up 38%, net loss widens

Adaptive Biotechnologies Corp

2022-Q2 EPS reported -$0.81 revenue$82,280,000

Revenue $43.7M (+13% YoY); MRD revenue $21.3M (+38%) on 53% test volume growth; Immune Medicine $22.4M (-3%).
Net loss $52.1M vs $49.3M in Q2 2021; operating expenses $96.2M (+9% YoY).
Updated FY2022 opex guidance to $410-415M (from $425-435M); revenue reaffirmed at $185-195M.
Expanded Medicare coverage of clonoSEQ for MRD assessment in DLBCL; signed pan-portfolio agreement with major partner.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.